New drug cocktail aims to tackle tough leukemias

NCT ID NCT03595917

Recruiting now Disease control Sponsor: Marlise Luskin, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called ABL001 together with three other medicines (dasatinib, prednisone, and blinatumomab) in people with BCR-ABL positive B-cell acute lymphoblastic leukemia or chronic myeloid leukemia in blast crisis. The study aims to find the safest dose of ABL001 and see if the combination helps control the disease. About 40 to 65 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABL001 (a targeted drug) combined with dasatinib, prednisone, and blinatumomab
What this could lead to: If successful, this combination could offer a new treatment option for people with certain types of leukemia that are hard to treat.
What could go wrong: This is an early phase 1 trial with only 40 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) blast phase chronic myelogenous leukemia, BCR-ABL1 positive Burkitt lymphoma leukemia, acute lymphocytic, susceptibility to, 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC MYELOID LEUKEMIA (CML) IN LYMPHOID BLAST CRISIS PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL)

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14203, United States
University of Chicago Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.